Key result
Intravenous ANP raises plasma adiponectin ~12% in CHF patients compared to saline.
Why the study?
Adiponectin is positively associated with plasma BNP levels in heart failure, prompting investigation into the functional relationship between natriuretic peptides and adiponectin.
Does intravenous human atrial natriuretic peptide (ANP) increase plasma adiponectin levels compared to saline in patients with chronic heart failure?
RCT (n=30)
Randomized 1:1 (n=15 vs n=15)
Does intravenous human atrial natriuretic peptide (ANP) increase plasma adiponectin levels compared to saline in patients with chronic heart failure?
Natriuretic peptides directly stimulate adiponectin production in human adipocytes and increase circulating adiponectin levels in patients with chronic heart failure, suggesting a potential cardioprotective mechanism for recombinant natriuretic peptide therapy.
Answers are grounded in this paper and cite their sources.
May support ANP as adiponectin modulator in HF; leaves open whether this improves clinical outcomes.
Objectives We investigated the functional relationship between natriuretic peptides and adiponectin by performing both experimental and clinical studies. Background Natriuretic peptides are promising candidates for the treatment of congestive heart failure (CHF) because of their wide range of beneficial effects on the cardiovascular system. Adiponectin is a cytokine derived from adipose tissue with various cardiovascular-protective effects that has been reported to show a positive association with plasma brain natriuretic peptide (BNP) levels in patients with heart failure. Methods The expression of adiponectin messenger ribonucleic acid (mRNA) and its secretion were examined after atrial natriuretic peptide (ANP) or BNP was added to primary cultures of human adipocytes in the presence or absence of HS142-1 (a functional type A guanylyl cyclase receptor antagonist). Changes of the plasma adiponectin level were determined in 30 patients with CHF who were randomized to receive intravenous ANP (0.025 microg/kg/min human ANP for 3 days, n = 15) or saline (n = 15). Results Both ANP and BNP dose-dependently enhanced the expression of adiponectin mRNA and its secretion, whereas such enhancement was inhibited by pre-treatment with HS142-1. The plasma adiponectin level was increased at 4 days after administration of human ANP compared with the baseline value (from 6.56 +/- 0.40 microg/ml to 7.34 +/- 0.47 microg/ml, p < 0.05), whereas there was no change of adiponectin in the saline group (from 6.53 +/- 0.57 microg/ml to 6.55 +/- 0.56 microg/ml). Conclusions Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF, which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy for heart failure.
No takes yet. Share an insight, caveat, or question.
Tsukamoto et al. (2009) conducted an RCT in Chronic heart failure (CHF) (n=30). Intravenous human atrial natriuretic peptide (ANP) vs. Saline was evaluated on Plasma adiponectin level at 4 days (microg/ml) (p=<0.05). Intravenous human ANP increased plasma adiponectin in CHF patients from 6.56 to 7.34 microg/ml at 4 days, with no change in the saline group.
Synapse has enriched 10 related papers. Consider them for comparative context: